SDB-006
跳至導覽
跳至搜尋
| File:SDB-006 structure.png | |
| 法律規範狀態 | |
|---|---|
| 法律規範 |
|
| 識別資訊 | |
| |
| CAS號 | 695213-59-3 check |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| E編碼 | {{#property:P628}} |
| CompTox Dashboard (EPA) |
|
| ECHA InfoCard | {{#property:P2566}}Module:EditAtWikidata第29行Lua錯誤：attempt to index field 'wikibase' (a nil value) |
| 化學資訊 | |
| 化學式 | C21H24N2O |
| 摩爾質量 | 320.44 g·mol−1 |
| 3D模型（JSmol） | |
| |
SDB-006是一種含氮有機化合物，分子式C
21H
24N
2O，帶有吲哚-3-甲酰胺結構，與其同系物SGT-56都為人工合成的大麻素[1][2]。
參考文獻[編輯]
- ^ Banister SD, Stuart J, Kevin RC, Edington A, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Hibbs DE, Glass M, Connor M, McGregor IS, Kassiou M. Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. ACS Chemical Neuroscience. August 2015, 6 (8): 1445–58 [2026-03-09]. PMID 25921407. doi:10.1021/acschemneuro.5b00107. （原始內容存檔於2023-09-24）.
- ^ Banister SD, Olson A, Winchester M, Stuart J, Edington AR, Kevin RC, Longworth M, Herrera M, Connor M, McGregor IS, Gerona RR, Kassiou M. The chemistry and pharmacology of synthetic cannabinoid SDB-006 and its regioisomeric fluorinated and methoxylated analogs. Drug Testing and Analysis. January 2018, 10 (7): 1099–1109. PMID 29350472. doi:10.1002/dta.2362.